Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression-Reference-Cited by-同舟云学术

Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression

Published:2014-02 Issue:1 Volume:68 Page:1-5
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Tafani Marco,De Santis Elena,Coppola Luigi,Perrone Giulietta A.,Carnevale Ilaria,Russo Andrea,Pucci Bruna,Carpi Angelo,Bizzarri Mariano,Russo Matteo A.

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference53 articles.

1. Thyroid gland: revised guidelines for the management of thyroid cancer;Boelaert;Nat Rev Endocrinol,2010

2. American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer;Cooper;Thyroid,2006

3. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy;Bommarito;Endocr Relat Cancer,2011

4. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells;Liu;J Clin Endocrinol Metab,2007

5. Molecular analysis of thyroid tumors;Nikiforov;Mod Pathol,2011

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential roles of HIF-1α in epithelial-mesenchymal transition and ferroptosis in tumor cells;Cellular Signalling;2024-10

2. Prediction of lymph node metastasis in patients with papillary thyroid cancer based on radiomics analysis and intraoperative frozen section analysis: A retrospective study;Clinical Otolaryngology;2024-04-15

3. Translocated HMGB3 is involved in papillary thyroid cancer progression by activating cytoplasmic TLR3 and transmembrane TREM1;Cell Cycle;2023-12-17

4. Aluminum induces neuroinflammation via P2X7 receptor activating NLRP3 inflammasome pathway;Ecotoxicology and Environmental Safety;2023-01

5. Associazione tra la sindrome metabolica e le caratteristiche clinico-patologiche del carcinoma papillifero tiroideo;L'Endocrinologo;2022-09-22